T. Rowe Price Investment Management, Inc. Tango Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 4,755,979 shares of TNGX stock, worth $34.6 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,755,979
Previous 4,321,551
10.05%
Holding current value
$34.6 Million
Previous $34.3 Million
18.92%
% of portfolio
0.03%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding TNGX
# of Institutions
119Shares Held
89.1MCall Options Held
2.6KPut Options Held
1K-
Trv Gp Iv, LLC Boston, MA19.2MShares$140 Million81.48% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$97 Million4.04% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$59.7 Million3.91% of portfolio
-
Nextech Invest Ag5.53MShares$40.3 Million8.96% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$38.4 Million1.32% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $641M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...